Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Bristol Myers Squibb's Accounts Payables fell 74.96% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year decrease of 74.96%. This contributed to the annual value of $3.6 billion for FY2025, which is 74.96% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Accounts Payables stood at $3.6 billion for Q4 2025, which was down 74.96% from $4.3 billion recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year Accounts Payables high stood at $5.4 billion for Q2 2025, and its period low was $2.6 billion during Q3 2022.
  • Moreover, its 5-year median value for Accounts Payables was $3.2 billion (2023), whereas its average is $3.4 billion.
  • Per our database at Business Quant, Bristol Myers Squibb's Accounts Payables tumbled by 2014.41% in 2022 and then surged by 4468.14% in 2025.
  • Over the past 5 years, Bristol Myers Squibb's Accounts Payables (Quarter) stood at $2.9 billion in 2021, then increased by 3.09% to $3.0 billion in 2022, then rose by 7.2% to $3.3 billion in 2023, then rose by 10.52% to $3.6 billion in 2024, then fell by 0.75% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q4 2025, $4.3 billion for Q3 2025, and $5.4 billion during Q2 2025.